“…Availability of injectable insulin formulation has been a breakthrough in diabetes management in achieving long-term glycemic control and preventing complications ( Baram et al., 2018 ; Heller et al, 2007 ; Moroder and Musiol, 2017 ; Owens et al., 2001 ; Xiong et al., 2019 ; Zaykov et al., 2016 ); it still, however, suffers from certain disadvantages including temperature-sensitive fibrillation in solution and development of subcutaneous tumor-like mass designated as “amyloidoma” at the site of injection ( Hua and Weiss, 2004 ; Ivanova et al., 2009 ; Nilsson, 2016 ; Woods et al., 2012 ; Yumlu et al, 2009 ). Worldwide efforts were thus made to develop thermostable insulin either by making recombinant insulin species with mutations or stabilizing native insulin with salts, Zn 2+ ions, and small molecules such as meta-cresol ( Frankær et al., 2017 ; Gong et al., 2014 ; Han et al., 2017 ; Kachooei et al, 2014 ; Lee et al, 2014 ; Patel et al, 2018 ; Saithong et al, 2018 ; Wang et al, 2011 ; Zheng and Lazo, 2018 ). However, small molecules are found to be toxic in long-term usage and are inefficient in optimally preventing fibrillation ( Teska et al., 2014 ; Weber et al., 2015 ).…”